Raymond James Financial
MLYS icon

Raymond James Financial’s Mineralys Therapeutics MLYS Stock Holding History

Raymond James Financial’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-24,677
Closed -$669K – 5516
2026
Q1 		$669K Sell
24,677
-297
-1% -$8.71K ﹤0.01% 4148
2025
Q4 		$906K Buy
+24,974
New +$1M ﹤0.01% 3846
2025
Q3 		– Sell
-141
Closed -$1.91K – 6029
2025
Q2 		$1.91K Buy
+141
New +$2.04K ﹤0.01% 6422

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Raymond James Financial's MLYS Position: Q2 2026 in Review

Raymond James Financial sold out of Mineralys Therapeutics (MLYS) in Q2 2026, closing a stake of 24,677 shares — an estimated $669K sold.

Raymond James Financial first reported a position in MLYS in Q2 2025 and held it in 3 quarters. The position peaked at $906K in Q4 2025. 225 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

  • Raymond James Financial reported no remaining Mineralys Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Raymond James Financial sold 24,677 Mineralys Therapeutics shares in Q2 2026, an estimated $669K.
  • Raymond James Financial first reported a position in Mineralys Therapeutics in Q2 2025 and held it in 3 quarters.
  • Raymond James Financial's Mineralys Therapeutics position peaked at $906K in Q4 2025.
  • 225 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.